Asian Pacific Journal of Allergy and Immunology

  • HOME
  • ABOUT
  • EDITORS
  • SUBMISSION
    • Online Submission
    • Author Instructions
  • ISSUE
    • Current
    • Early Online
    • Archives
  • PERMISSIONS
  • CONTACT
  • ADVERTISE
Home
 / 
Review Article
 / 
Asthma does not increase COVID-19 mortality and poor outcomes: A systematic review and meta-analysis

April 26, 2021
Review Article

Asthma does not increase COVID-19 mortality and poor outcomes: A systematic review and meta-analysis

Arto Yuwono Soeroto,1,2 Aga Purwiga,2 Emmy H. Pranggono,1,2 Rully M.A Roesli2

1 Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia
2 Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia

Abstract

Background: The Center for Disease Control and Prevention (CDC) has mentioned Coronavirus Disease 2019 (COVID-19) patients with moderate or severe asthma as a high risk group for severe illness. While WHO mentioned only chronic respiratory diseases, not specifically asthma as a risk factor for severe illness. There has been asthma prevalence discrepancy in studies of COVID-19 across the world.
Objective: This meta-analysis aims to investigate the association between asthma and composite poor outcome in patients with coronavirus disease (COVID-19).
Methods: We conducted a systematic literature search from PubMed and Embase database. We included all original research articles with adult COVID-19 patients > 18 years old and had information related to asthma as a risk factor. Studies with outcomes consisting of mortality, severe COVID-19, use of mechanical ventilation, ICU admission, and hospital admission were included in this study. The outcomes of interest were divided into severe COVID-19, mortality and other poor outcomes.
Results: Eleven studies were included in meta-analysis with a total of 6,046 patients. Asthma was not associated with composite poor outcomes with OR = 0.92 (95%CI 0.71–1.19, p = 0.61, and I2 = 8.49%). Furthermore, subgroup analysis showed that asthma was not associated with severe COVID (p = 0.76), mortality (p = 0.45), and other poor outcomes (p = 0.28).
Conclusion: Our study showed that asthma was not associated with severe COVID-19, mortality, and other poor outcomes in patients with COVID-19.
Key words: Asthma, Corticosteroid, COVID-19, mortality, poor outcome

Full Text
Vol. 39, No. 2
Asthma, Corticosteroid, COVID-19, Mortality, Poor Outcome

Categories

  • Announcement (1)
  • Case Report (23)
  • Early Online (93)
  • Original Article (223)
  • Review Article (29)

Key words

allergen Allergic rhinitis Allergy Anaphylaxis Asthma atopic dermatitis child Children Chlorhexidine chronic rhinosinusitis chronic spontaneous urticaria Chronic Urticaria COVID-19 cytokine depression diagnosis drug allergy Drug hypersensitivity efficacy Epidemiology food allergy Food hypersensitivity house dust mite IgE Immunotherapy obstructive sleep apnea Omalizumab prevalence primary immunodeficiency Quality of life Questionnaire Reliability risk factor risk factors safety SARS-CoV-2 Sensitization Severe asthma Skin prick test Specific IgE Thai treatment urticaria vaccine Vitamin D
Asian Pacific Journal of Allergy and Immunology

Support Contact

Managing Editor
Ms. Patrawadee Pitakpolrat
E-mail: managingeditor@apjai-journal.org

Production Editor
Ms. Chanita Jangsawang
E-mail: chanita.j@apjai-journal.org

Asian Pacific Journal of Allergy and Immunology © 2025 All rights reserved.
All rights reserved | Privacy Policy